EBR designed its WiSE system to significantly expand the population of patients who could benefit from CRT. The leadless ...

Imricor Medical Systems announced that it commenced a trial by completing its first-in-human ventricular ablation procedure.

EBR Systems, Inc. (ASX: EBR) has received FDA approval of the WiSE® System, which marks a significant leap forward in the treatment of heart failure. Unlike conventional CRT, the WiSE System is the ...

Field Medical Inc., a pioneer in cardiac pulsed field ablation (PFA) technology, today announced the successful closing of $40 million in Series A financing. The round includes $20 million in new ...

Field Medical Inc., a pioneer in cardiac pulsed field ablation (PFA) technology, today announced the successful closing of $40 million ...

Wide complexes; because they come from the ventricles and do not use the normal ventricular conduction system, action potentials need to travel from myocyte to myocyte, which is much slower ...

Unlike conventional CRT, the WiSE System is the first and only to deliver leadless left ventricular endocardial pacing (LVEP), that closely aligns with the heart's natural conduction pathway.

"Now, the WiSE System brings a leadless solution to left ventricular pacing, eliminating the biggest limitation of conventional CRT: the lead. This is a game-changer for patients who were ...